Seamus Fernandez
Stock Analyst at Guggenheim
(4.69)
# 71
Out of 5,182 analysts
127
Total ratings
61.7%
Success rate
28.3%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $72 | $60.17 | +19.66% | 15 | Apr 8, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,168 → $1,163 | $927.03 | +25.45% | 24 | Mar 30, 2026 | |
| GENB Generate Biomedicines | Initiates: Buy | $30 | $12.45 | +140.96% | 1 | Mar 24, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $130 → $160 | $92.20 | +73.54% | 9 | Mar 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $25 → $30 | $18.36 | +63.40% | 3 | Mar 19, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $25 → $34 | $14.45 | +135.29% | 4 | Mar 16, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $34 → $35 | $24.53 | +42.68% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $88.69 | +61.24% | 4 | Feb 27, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $27 | $6.47 | +317.31% | 1 | Feb 3, 2026 | |
| PCVX Vaxcyte | Reiterates: Buy | $116 | $62.35 | +86.05% | 5 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $140 | $50.75 | +175.86% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $77 → $88 | $33.77 | +160.59% | 5 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.06 | - | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $5.67 | +94.00% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.85 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $30.58 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $119.07 | +2.46% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $58.35 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.50 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $40.52 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $151.97 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.39 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $4.25 | +1,170.59% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $34.55 | +30.25% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $204.80 | -81.45% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $27.56 | +37.88% | 3 | Jan 31, 2018 |
Bristol-Myers Squibb Company
Apr 8, 2026
Reiterates: Buy
Price Target: $72
Current: $60.17
Upside: +19.66%
Eli Lilly and Company
Mar 30, 2026
Maintains: Buy
Price Target: $1,168 → $1,163
Current: $927.03
Upside: +25.45%
Generate Biomedicines
Mar 24, 2026
Initiates: Buy
Price Target: $30
Current: $12.45
Upside: +140.96%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $130 → $160
Current: $92.20
Upside: +73.54%
Amylyx Pharmaceuticals
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $18.36
Upside: +63.40%
Tenax Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $25 → $34
Current: $14.45
Upside: +135.29%
Arcutis Biotherapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $24.53
Upside: +42.68%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $88.69
Upside: +61.24%
Sagimet Biosciences
Feb 3, 2026
Initiates: Buy
Price Target: $27
Current: $6.47
Upside: +317.31%
Vaxcyte
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $62.35
Upside: +86.05%
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $50.75
Upside: +175.86%
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $33.77
Upside: +160.59%
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $48.06
Upside: -
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $5.67
Upside: +94.00%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $8.85
Upside: -
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $30.58
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $119.07
Upside: +2.46%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $58.35
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.50
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $40.52
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $151.97
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.39
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $4.25
Upside: +1,170.59%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $34.55
Upside: +30.25%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $204.80
Upside: -81.45%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $27.56
Upside: +37.88%